Sign Up Today and Learn More About Neuralink Stock
Invest in or calculate the value of your shares in Neuralink or other pre-IPO companies through EquityZen's platform.
Neuralink Stock (NEUR)
Neuralink is a neurotechnology company that focuses on developing brain-computer interfaces designed to treat neurological disorders.
About Neuralink Stock
Founded
2017
Headquarters
Fremont, CA, US
Total Funding
1.3B
Industries
Hardware, Software, Science and Engineering
Neuralink is a neurotechnology company developing implantable brain-computer interfaces (BCIs). The company's technology is designed to help individuals with neurological disorders restore mobility and communication abilities. Neuralink is also developing robotic surgical systems to perform the implantation procedure with high accuracy. By advancing implantable brain devices, Neuralink seeks to restore user independence and improve lives.
Neuralink Press Mentions
Stay in the know about the latest news on Neuralink
Elon Musk’s Companies Suffer Mass Employee Exits, Threatening Innovation
webpronews • Oct 07, 2025
Musk’s Neuralink Submits Brain Implant Patient Data to Journal
livemint • Oct 05, 2025
Filevine LEX Summit 2025: Alex Spiro on Winning Trials and Harnessing AI
techbuzznews • Oct 03, 2025
Nvidia CEO Jensen Huang calls Elon Musk the 'ultimate GPU'
businessinsider • Oct 02, 2025
Elon Musk becomes first person to hit $500 billion in net worth: All you need to know
economictimes • Oct 02, 2025
Investors in Neuralink
Discover investors in Neuralink stock and explore their portfolio companies
Neuralink Management
Leadership team at Neuralink
CEO
Jared Birchall
Co-Founder & Co-CEO
Elon Musk
Join now and verify your accreditation status to gain access to:
- Neuralink Current Valuation
- Neuralink Stock Price
- Neuralink Management
- Available deals in Neuralink and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Neuralink Cap Table and Funding History by Share Class and Liquidity Preferences
- Neuralink Revenue and Financials
- Neuralink Highlights
- Neuralink Business Model
- Neuralink Risk Factors
- Neuralink Research Report from SACRA Research
Neuralink Key Facts
- Clinical Trial Expansion and Growing Patient Base: Neuralink has significantly expanded its clinical footprint beyond its initial single-patient trial. As of September 2025, the company has successfully implanted its N1 brain chip in 12 people, a four-fold increase since the beginning of the year. This includes the first human trials outside the United States, with implantations in Canada and plans for studies in the United Kingdom and the United Arab Emirates. This expansion signals a crucial shift from a single-case study to a broader clinical validation, essential for scaling a medical device.
- Substantial Funding and Soaring Valuation: In May 2025, Neuralink closed a $650 million funding round at a reported $9 billion valuation, more than double its valuation from just two years prior. This funding, with participation from major investors like Sequoia Capital and Lightspeed, demonstrates strong investor confidence in the company's technology and its commercialization roadmap. The capital will be used to accelerate clinical trials, expand its hardware development program, and hire more engineers, positioning the company to maintain its technological lead.
- Regulatory Milestones and Product Pipeline: The company has received multiple "Breakthrough Device Designations" from the FDA for its technology, which fast-tracks the review process for devices that could provide more effective treatment for life-threatening or irreversibly debilitating diseases. These designations, for both its "Telepathy" system (for communication) and "Blindsight" technology (for vision restoration), signal regulatory confidence in the potential of Neuralink's platform. This strategic focus on a diversified product pipeline for various neurological conditions strengthens its long-term growth prospects.
- Intense Competition and Proven Alternatives: While Neuralink generates considerable buzz, it faces significant competition from well-established neurotech companies and other ventures. For instance, Synchron, Inc., a direct competitor, has an implant that can be inserted through a blood vessel, making its procedure less invasive than Neuralink's. Other competitors like Blackrock Neurotech have been developing and commercializing brain-computer interfaces for years. This competitive environment, combined with the proven track records of these companies, poses a risk to Neuralink's market share as they vie for patients, research partners, and investment.
- Ethical and Regulatory Scrutiny: Neuralink is under intense scrutiny from medical professionals and bioethicists, which could impact its operational performance and growth.The company's recent expansion into Canadian clinical trials has been met with public concern from some doctors who question a lack of transparency about the risks of the invasive procedure, such as what happens if the device degrades or gets infected.The company has been criticized for not registering its clinical trials on the standard government database, further widening the "trust gap" and potentially complicating its ability to recruit future patients and secure regulatory approvals.
- Technical and Operational Failures: The company's first human trial faced a significant technical setback when the device's electrode threads began to detach from the brain tissue within weeks of implantation. The company, through public reports, has acknowledged this issue, which caused a drop in data transmission. While Neuralink claims to have fixed the problem with a software patch, this malfunction raises concerns about the device's long-term durability and reliability. These technical hurdles, along with past allegations of animal cruelty and unsafe practices, create a risk of reputational damage and could lead to increased regulatory oversight.
Trading Neuralink Stock
How to invest in Neuralink stock?
Accredited investors can buy pre-IPO stock in companies like Neuralink through EquityZen funds. These investments are made available by existing Neuralink shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Neuralink stock?
Shareholders can sell their Neuralink stock through EquityZen's private company marketplace. EquityZen's network includes over 390K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 48K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
